Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPa blockade immunotherapy via metabolic reprograming [dataset 1]

Innate immune checkpoint has emerging as a highly potential target for cancer immunotherapy in recent years. The CD47-SIRPa axis is the best-studied innate checkpoint in cancer. However, the transcription profile of tumor cell duiring CD47-SIRPa blockade therapy remains unclear. Overall design: C57BL/6 mice (n=3 per group) transplanted s.c. with 5×10E5 MC38 cells were treated i.t. with 50 µg CV-1 or hIgG every three days. Two days after the third treatment, CD45- cells were sorted for the generation of RNA-seq libraries.